TIMI 12 evaluated the safety and efficacy of the oral GP IIb/IIa inhibitor sibrafiban for the treatment of patients with a recent acute coronary syndrome.
TIMI 12 evaluated the safety and efficacy of the oral GP IIb/IIa inhibitor sibrafiban for the treatment of patients with a recent acute coronary syndrome.